You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Mounjaro® (tirzepatide) be used in patients with lipedema?
No efficacy or safety data are available for tirzepatide use in lipedema as it has not been studied by Lilly. Lipedema was not an exclusion in clinical trials, but no subanalyses were done to confirm enrollment or outcomes for these patients.
See important safety information, including boxed warning, in the attached prescribing information.
Can Mounjaro® (tirzepatide) be used in patients with lipedema?
No efficacy or safety data are available for tirzepatide use in lipedema as it has not been studied by Lilly. Lipedema was not an exclusion in SURPASS trials, but no subanalyses were done to confirm outcomes for these patients.
Treatment Recommendations
Lipedema is not listed as a contraindication for tirzepatide.
Lipedema was not an exclusion criterion in SURPASS studies, but no subanalyses were done to confirm enrollment or outcomes for these patients.
Eli Lilly and Company cannot provide a recommendation on whether to use tirzepatide in a patient with lipedema. The health care practitioner may use the information provided, the patient’s prior medical history and concomitant medications, and other individual factors in developing a treatment plan. The health care practitioner should consider potential risks and benefits of treatment options and monitor appropriately.
Eli Lilly and Company recognize that publications on this topic may exist in scientific literature for GLP-1 receptor agonists. Publications authored by independent individuals or groups employing different research methodologies, may be subject to varying scientific rigor and interpretations. For this reason, Lilly primarily limits responses to data generated from our own sponsored research programs. We encourage the prescribing healthcare provider to exercise clinical judgement to obtain and evaluate external literature for sound scientific merit, clinical relevance, and generalizability.
Enclosed Prescribing Information
MOUNJARO® (tirzepatide) Injection, for subcutaneous use, Lilly
Date of Last Review: August 27, 2026